Vaccine immunotherapy
A composition for treating cancer, including synergistic amounts of a primary cell-derived biologic having the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ, and a cancer vaccine having at least one antigen. A composition comprising synergistic amounts of the primary cell-derived biologic in combination with at least one adjuvant. A method of treating cancer by administering the composition. A method of reversing immune suppression and gaining immunity to cancer. A method of producing an immune response to an exogenous antigen. A method of enhancing an immune response in a patient by administering the primary cell-derived biologic in combination with at least one adjuvant, and enhancing the immune response of the patient by a synergistic interaction of the primary cell-derived biologic and the adjuvant. A method of increasing function of an immune system.
1. A composition for enhancing an immune response in a patient, comprising:
(a) a primary cell-derived biologic comprising the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ; and
(b) a composition comprising at least one adjuvant selected from the group consisting of CpG, polyI:C and recombinant IFN-γ,
wherein the combination of (a) and (b) acts synergistically to enhance the immune response in the patient.
2. The composition of claim 1 , wherein the composition in (b) comprises CpG, polyI:C and recombinant IFN-γ.
3. The composition of claim 1 , wherein the primary cell-derived biologic comprises 60-6,000 picograms/mL of IL-1, 600-60,000 picograms/mL of IL-2, 60-6,000 picograms/mL of IL-6, 6,000-600,000 picograms/mL of IL-8, 200-20,000 picograms/mL of TNF-α, and 200-20,000 picograms/mL of IFN-γ.
4. A method of enhancing an immune response in a patient, comprising administering the composition of claim 1 to the patient, wherein the combination of (a) and (b) acts synergistically to enhance the immune response in the patient.
5. The method of claim 4 , further including the step of administering at least one exogenous antigen.
6. The method of claim 4 , wherein the composition in (b) comprises CpG, polyI:C and recombinant IFN-γ.
7. The method of claim 4 , wherein the primary cell-derived biologic comprises 60-6,000 picograms/mL of IL-1, 600-60,000 picograms/mL of IL-2, 60-6,000 picograms/mL of IL-6,000-600,000picograms/mL of IL-8, 200-20,000 picograms/mL of TNF-α, and 200-20,000 picograms/mL of IFN-γ.
8. A method of enhancing an immune response in a patient, comprising administering to the patient:
(a) a primary cell-derived biologic comprising the cytokines IL-1, IL-2, IL-6, IL-8, TNF-α, and IFN-γ; and
(b) a composition comprising at least one adjuvant selected from the group consisting of CpG, polyI:C and recombinant IFN-γ,
wherein the combination of (a) and (b) acts synergistically to enhance the immune response in the patient, and wherein (a) and (b) are administered separately.
9. The method of claim 8 , wherein the composition in (b) comprises CpG, polyI:C and recombinant IFN-γ.
10. The method of claim 8 , wherein the primary cell-derived biologic comprises 60-6,000 picograms/mL of IL-1, 600-60,000 picograms/mL of IL-2, 60-6,000 picograms/mL of IL-6, 6,000-600,000 picograms/mL of IL-8, 200-20,000 picograms/mL of TNF-α, and 200-20,000picograms/mL of IFN-γ.
11. The method of claim 8 , further including the step of administering at least one exogenous antigen.